LB Pharmaceuticals, a US biotech company, ends the 2025 biotech IPO drought by raising $285m through a Nasdaq listing. The company is focusing on developing treatments for schizophrenia and is offering 19 million shares at $15 each. The IPO funds will support the development of their lead candidate, LB-102.

The company announced an upsized offering, potentially increasing the total funds by $42.7m if underwriters take an additional 2.85 million shares at the same price. LB Pharmaceuticals began trading under the ticker LBRX on September 11, with the offering expected to close on September 12.

LB Pharmaceuticals plans to allocate $133m of the IPO funds for a phase III study of LB-102 in schizophrenia and $25m for a phase II trial in bipolar disorder. The company did not disclose the updated investment allocation based on the upsized offering.

This IPO marks a revival in the 2025 biotech IPO landscape, as no companies had made sizeable raises since February. LB Pharmaceuticals’ successful listing comes after a challenging IPO landscape impacted by market volatility and macroeconomic policy shifts in the US.

The Trump administration’s impact on the biopharmaceutical industry has introduced uncertainty that could affect investor confidence. Despite the challenges, biotech companies like LB Pharmaceuticals are navigating the IPO landscape and raising significant funds for drug development and research.

Read more at Yahoo Finance: LB Pharmaceuticals tops 2025 biotech IPO list with $285m Nasdaq debut